CN115005434A - Composition for improving microcirculation, liquid preparation, and preparation method and application thereof - Google Patents
Composition for improving microcirculation, liquid preparation, and preparation method and application thereof Download PDFInfo
- Publication number
- CN115005434A CN115005434A CN202210851308.1A CN202210851308A CN115005434A CN 115005434 A CN115005434 A CN 115005434A CN 202210851308 A CN202210851308 A CN 202210851308A CN 115005434 A CN115005434 A CN 115005434A
- Authority
- CN
- China
- Prior art keywords
- peptide
- composition
- fish collagen
- equal
- collagen peptide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 111
- 238000002360 preparation method Methods 0.000 title claims abstract description 59
- 230000004089 microcirculation Effects 0.000 title claims abstract description 46
- 239000007788 liquid Substances 0.000 title claims abstract description 45
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 207
- 102000008186 Collagen Human genes 0.000 claims abstract description 114
- 108010035532 Collagen Proteins 0.000 claims abstract description 114
- 229920001436 collagen Polymers 0.000 claims abstract description 114
- 241000251468 Actinopterygii Species 0.000 claims abstract description 113
- 102000016942 Elastin Human genes 0.000 claims abstract description 98
- 108010014258 Elastin Proteins 0.000 claims abstract description 98
- 229920002549 elastin Polymers 0.000 claims abstract description 98
- 235000003145 Hippophae rhamnoides Nutrition 0.000 claims abstract description 80
- 241000229143 Hippophae Species 0.000 claims abstract description 76
- 235000011389 fruit/vegetable juice Nutrition 0.000 claims abstract description 45
- 210000004204 blood vessel Anatomy 0.000 claims abstract description 32
- 230000011132 hemopoiesis Effects 0.000 claims abstract description 21
- 230000001737 promoting effect Effects 0.000 claims abstract description 21
- 241000283690 Bos taurus Species 0.000 claims description 54
- 210000003041 ligament Anatomy 0.000 claims description 54
- 235000015203 fruit juice Nutrition 0.000 claims description 53
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 37
- 101800005149 Peptide B Proteins 0.000 claims description 31
- 108010005636 polypeptide C Proteins 0.000 claims description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 11
- 235000012055 fruits and vegetables Nutrition 0.000 claims description 10
- 239000002562 thickening agent Substances 0.000 claims description 10
- 240000000950 Hippophae rhamnoides Species 0.000 claims description 9
- 238000007872 degassing Methods 0.000 claims description 8
- 239000012669 liquid formulation Substances 0.000 claims description 8
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 claims description 5
- 239000002253 acid Substances 0.000 claims description 5
- 229930003944 flavone Natural products 0.000 claims description 5
- 150000002212 flavone derivatives Chemical class 0.000 claims description 5
- 235000011949 flavones Nutrition 0.000 claims description 5
- 108010091748 peptide A Proteins 0.000 claims description 5
- 230000001954 sterilising effect Effects 0.000 claims description 5
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 claims description 5
- 239000000796 flavoring agent Substances 0.000 claims description 3
- 235000019634 flavors Nutrition 0.000 claims description 3
- 238000000034 method Methods 0.000 claims description 3
- 238000002156 mixing Methods 0.000 claims description 3
- 238000000265 homogenisation Methods 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 45
- 238000002474 experimental method Methods 0.000 abstract description 10
- 230000009286 beneficial effect Effects 0.000 abstract description 2
- 150000001875 compounds Chemical class 0.000 abstract description 2
- 238000009776 industrial production Methods 0.000 abstract description 2
- 231100000331 toxic Toxicity 0.000 abstract 1
- 230000002588 toxic effect Effects 0.000 abstract 1
- 208000027418 Wounds and injury Diseases 0.000 description 13
- 230000002792 vascular Effects 0.000 description 13
- 208000014674 injury Diseases 0.000 description 12
- 230000006378 damage Effects 0.000 description 11
- 239000002137 L01XE24 - Ponatinib Substances 0.000 description 10
- 230000003511 endothelial effect Effects 0.000 description 10
- PHXJVRSECIGDHY-UHFFFAOYSA-N ponatinib Chemical compound C1CN(C)CCN1CC(C(=C1)C(F)(F)F)=CC=C1NC(=O)C1=CC=C(C)C(C#CC=2N3N=CC=CC3=NC=2)=C1 PHXJVRSECIGDHY-UHFFFAOYSA-N 0.000 description 10
- 229960001131 ponatinib Drugs 0.000 description 10
- 210000004369 blood Anatomy 0.000 description 9
- 239000008280 blood Substances 0.000 description 9
- 238000012360 testing method Methods 0.000 description 8
- 239000013641 positive control Substances 0.000 description 7
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 6
- 241000252212 Danio rerio Species 0.000 description 6
- 229960001138 acetylsalicylic acid Drugs 0.000 description 6
- 230000003394 haemopoietic effect Effects 0.000 description 6
- LQRJAEQXMSMEDP-XCHBZYMASA-N peptide a Chemical compound N([C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](C)C(=O)NCCCC[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)C(\NC(=O)[C@@H](CCCCN)NC(=O)CNC(C)=O)=C/C=1C=CC=CC=1)C(N)=O)C(=O)C(\NC(=O)[C@@H](CCCCN)NC(=O)CNC(C)=O)=C\C1=CC=CC=C1 LQRJAEQXMSMEDP-XCHBZYMASA-N 0.000 description 6
- 235000003935 Hippophae Nutrition 0.000 description 5
- 150000001413 amino acids Chemical class 0.000 description 5
- 208000007502 anemia Diseases 0.000 description 5
- 230000006872 improvement Effects 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 241000962514 Alosa chrysochloris Species 0.000 description 4
- 230000002411 adverse Effects 0.000 description 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
- 238000013329 compounding Methods 0.000 description 4
- 210000004177 elastic tissue Anatomy 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 230000008439 repair process Effects 0.000 description 4
- 238000010186 staining Methods 0.000 description 4
- JRBJSXQPQWSCCF-UHFFFAOYSA-N 3,3'-Dimethoxybenzidine Chemical compound C1=C(N)C(OC)=CC(C=2C=C(OC)C(N)=CC=2)=C1 JRBJSXQPQWSCCF-UHFFFAOYSA-N 0.000 description 3
- 229920002752 Konjac Polymers 0.000 description 3
- 241000269851 Sarda sarda Species 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 210000002565 arteriole Anatomy 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 210000003989 endothelium vascular Anatomy 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 235000010485 konjac Nutrition 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 230000002195 synergetic effect Effects 0.000 description 3
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 201000001320 Atherosclerosis Diseases 0.000 description 2
- 206010011224 Cough Diseases 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- 206010062717 Increased upper airway secretion Diseases 0.000 description 2
- 208000007536 Thrombosis Diseases 0.000 description 2
- 240000000851 Vaccinium corymbosum Species 0.000 description 2
- 235000003095 Vaccinium corymbosum Nutrition 0.000 description 2
- 235000017537 Vaccinium myrtillus Nutrition 0.000 description 2
- 206010052428 Wound Diseases 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 2
- 239000003146 anticoagulant agent Substances 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 230000036772 blood pressure Effects 0.000 description 2
- 235000021014 blueberries Nutrition 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- 201000006549 dyspepsia Diseases 0.000 description 2
- 210000003038 endothelium Anatomy 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 235000013312 flour Nutrition 0.000 description 2
- 239000001630 malic acid Substances 0.000 description 2
- 235000011090 malic acid Nutrition 0.000 description 2
- 210000005036 nerve Anatomy 0.000 description 2
- 208000026435 phlegm Diseases 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 239000012192 staining solution Substances 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 description 2
- 239000005483 tyrosine kinase inhibitor Substances 0.000 description 2
- 150000004917 tyrosine kinase inhibitor derivatives Chemical class 0.000 description 2
- 210000000264 venule Anatomy 0.000 description 2
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 201000000736 Amenorrhea Diseases 0.000 description 1
- 206010001928 Amenorrhoea Diseases 0.000 description 1
- 244000247812 Amorphophallus rivieri Species 0.000 description 1
- 235000001206 Amorphophallus rivieri Nutrition 0.000 description 1
- 244000144730 Amygdalus persica Species 0.000 description 1
- 101100227322 Caenorhabditis elegans fli-1 gene Proteins 0.000 description 1
- 241001117772 Elaeagnaceae Species 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 229920002148 Gellan gum Polymers 0.000 description 1
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 235000017784 Mespilus germanica Nutrition 0.000 description 1
- 244000182216 Mimusops elengi Species 0.000 description 1
- 235000000560 Mimusops elengi Nutrition 0.000 description 1
- 240000000249 Morus alba Species 0.000 description 1
- 235000008708 Morus alba Nutrition 0.000 description 1
- 101100281205 Mus musculus Fli1 gene Proteins 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 235000006040 Prunus persica var persica Nutrition 0.000 description 1
- 244000294611 Punica granatum Species 0.000 description 1
- 235000014360 Punica granatum Nutrition 0.000 description 1
- 241000220317 Rosa Species 0.000 description 1
- 235000017276 Salvia Nutrition 0.000 description 1
- 240000007164 Salvia officinalis Species 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 235000007837 Vangueria infausta Nutrition 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 241001593968 Vitis palmata Species 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- 231100000540 amenorrhea Toxicity 0.000 description 1
- 230000003872 anastomosis Effects 0.000 description 1
- 230000000702 anti-platelet effect Effects 0.000 description 1
- 230000002785 anti-thrombosis Effects 0.000 description 1
- 235000015197 apple juice Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 230000036996 cardiovascular health Effects 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000000875 corresponding effect Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 229920001971 elastomer Polymers 0.000 description 1
- 210000002257 embryonic structure Anatomy 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 230000004720 fertilization Effects 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 239000000216 gellan gum Substances 0.000 description 1
- 235000010492 gellan gum Nutrition 0.000 description 1
- 235000021562 grape concentrated juice Nutrition 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000005732 intercellular adhesion Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 239000000252 konjac Substances 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 210000002464 muscle smooth vascular Anatomy 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 235000020418 red date juice Nutrition 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 230000036559 skin health Effects 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 210000005070 sphincter Anatomy 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000009261 transgenic effect Effects 0.000 description 1
- 230000008736 traumatic injury Effects 0.000 description 1
- 230000004218 vascular function Effects 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/02—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation containing fruit or vegetable juices
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/52—Adding ingredients
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/18—Peptides; Protein hydrolysates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Nutrition Science (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Mycology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
The invention discloses a composition for improving microcirculation, a liquid preparation, and a preparation method and application thereof, and relates to the technical field of compositions. The composition for improving microcirculation comprises at least one of fish collagen peptide and elastin peptide and sea buckthorn juice. Experiments show that the compound of the fish collagen peptide and the sea buckthorn juice or the elastin peptide and the sea buckthorn juice has the efficacy of promoting hematopoiesis and improving the diameter of blood vessels, thereby being beneficial to improving the microcirculation of organisms. The composition for improving the microcirculation is natural in components, safe to organisms and free of toxic and side effects, and the preparation method of the liquid preparation containing the composition for improving the microcirculation is simple and suitable for industrial production.
Description
Technical Field
The invention relates to the technical field of compositions, in particular to a composition for improving microcirculation, a liquid preparation, and a preparation method and application thereof.
Background
Microcirculation refers to the circulation of blood between arterioles and venules, primarily for exchange of substances, and also regulates blood flow and tissue perfusion, affecting blood pressure and response to inflammation, including edema (swelling) and the like. Typical microcirculation generally consists of seven parts, namely arteriole, posterior arteriole, anterior sphincter of capillary vessel, true capillary vessel, blood-circulating capillary vessel, artery-vein anastomosis branch and venule, wherein the regulation of microcirculation influences the blood flow of microcirculation mainly by regulating the relaxation activity of vascular smooth muscle through nerve and body fluid, and once the microcirculation is broken, the body is in an unstable state.
The vascular endothelium responds to signals such as blood pressure changes, inflammatory responses, and levels of circulating active substances, and responds in a regulatory manner to maintain normal vascular function and blood supply. Vascular endothelial injury can affect blood microcirculation and increase the risk of atherosclerosis and thrombosis. Microcirculation is disturbed, and the exchange of substances between blood and tissue fluid is affected, so that the physiological functions of each organ are directly affected, and myocardial infarction, stroke and the like can be even caused in severe cases.
At present, the microcirculation is mainly treated by medicines, such as aspirin, compound salvia dropping pills and the like, but the medicines are only used for treatment and are not suitable for prevention and health care. Nowadays, lifestyle, diet, stress and the like make many people in sub-health state, and it is urgently needed to provide a safe product for improving microcirculation and preventing more serious consequences caused by microcirculation disorder.
In addition, Ponatinib (Ponatinib) is a third-generation Tyrosine Kinase Inhibitor (TKI) and is suitable for treating leukemia, but the drug can cause thrombosis and induce vascular endothelial injury to influence microcirculation, and no suitable product is disclosed at present to play a role in improving ischemic anemia and vascular endothelial injury caused by Ponatinib.
Disclosure of Invention
The invention aims to overcome the defects of the prior art and provide a composition for improving microcirculation, a liquid preparation, a preparation method and an application thereof.
In order to achieve the purpose, the technical scheme adopted by the invention is as follows:
a composition for improving microcirculation, the composition comprising at least one of fish collagen peptide, elastin peptide and sea buckthorn juice.
At present, fish collagen peptide and elastin peptide are mainly used for improving skin health, and sea buckthorn is mainly used in the field of oxidation resistance and has not been disclosed to be applied in the field of improving microcirculation.
Preferably, the elastin peptide is bovine ligament elastin peptide.
Preferably, the composition comprises fish collagen peptide, bovine ligament elastin peptide and sea buckthorn juice.
Preferably, in the composition, the mass ratio of the fish collagen peptide to the elastin peptide is (3-6): (0.075-0.2).
Preferably, the fish collagen peptide comprises at least one of fish collagen peptide a, fish collagen peptide B, fish collagen peptide C;
the fish collagen peptide A contains more than or equal to 85 wt% of peptides with the molecular weight of less than or equal to 500 Da;
in the fish collagen peptide B, the content of peptides with the molecular weight of less than or equal to 1kDa is greater than or equal to 85 wt.%, and the content of peptides with the molecular weight of less than or equal to 500Da is less than or equal to 60 wt.%;
in the fish collagen peptide C, the content of peptides with the molecular weight of less than or equal to 3kDa is greater than or equal to 75 wt.%, the content of peptides with the molecular weight of less than or equal to 1kDa is less than or equal to 70 wt.%, and the content of peptides with the molecular weight of less than or equal to 500Da is less than or equal to 60 wt.%.
Further preferably, the fish collagen peptide is fish collagen peptide B; the bovine ligament elastin peptide has a molecular weight of less than or equal to 10kDa, wherein the content of peptides with molecular weights of less than or equal to 5kDa is greater than or equal to 80 wt.%.
Preferably, the fructus Hippophae juice contains total flavone more than 80mg/100g and total acid (calculated as malic acid) more than 3 wt.%.
In addition, the invention also discloses a liquid preparation which comprises the composition for improving microcirculation.
The liquid preparation comprises the following components in percentage by mass: 3-6% of fish collagen peptide, 0.075-0.2% of elastin peptide, 60% of sea buckthorn fruit juice and the balance of water.
In addition, the liquid preparation can also contain fruit and vegetable juice, a thickening agent and essence, and comprises the following components in percentage by mass: 3-6% of fish collagen peptide, 0.075-0.2% of elastin peptide, 60% of sea-buckthorn fruit juice, 0.01-2% of thickening agent, 0-2% of essence, 5-30% of fruit and vegetable juice and the balance of water.
Meanwhile, the invention also discloses a preparation method of the liquid preparation, which comprises the following steps:
(1) uniformly mixing the components according to the proportion to obtain a mixture;
(2) and homogenizing, degassing and sterilizing the mixture to obtain the liquid preparation.
In the step (2), the homogenizing pressure is 14-22 MPa, and the degassing vacuum degree is-0.05-0.06 MPa.
In addition, the invention also discloses application of the liquid preparation in preparing a product for promoting hematopoiesis and application of the liquid preparation in preparing a product for improving the diameter of blood vessels.
Compared with the prior art, the invention has the beneficial effects that:
the composition prepared by compounding at least one of the fish collagen peptide and the elastin peptide with the sea buckthorn fruit juice has a good function of improving microcirculation; in addition, by compounding bovine ligament elastin peptide, fish collagen peptide and sea buckthorn fruit juice, the hematopoiesis promoting effect of the composition and the protection effect on vascular endothelium are synergistically improved. In addition, the composition has greatly enhanced microcirculation improving performance by selecting the molecular weight of the fish collagen peptide. The composition and the liquid preparation have natural raw materials and are safe to human bodies, fruit and vegetable juice, essence and the like can be added according to needs to improve the flavor, the composition and the liquid preparation can be used for prevention, are suitable for being eaten or taken by people with sub-health bodies, have simple preparation methods and are suitable for industrial production.
Drawings
FIG. 1 is a heart staining intensity test chart of the liquid preparations of experimental groups 1-12;
FIG. 2 is a diagram of the hematopoietic effect of the liquid preparations of experimental groups 1 to 12;
FIG. 3 is a blood vessel diameter test chart of the liquid preparations of experimental groups 1 to 12;
FIG. 4 is a graph showing the efficacy of the liquid preparations of the experimental groups 1 to 12 in improving blood vessel diameter.
Detailed Description
To better illustrate the objects, aspects and advantages of the present invention, the present invention will be further described with reference to the accompanying drawings and specific embodiments.
The composition for improving microcirculation comprises at least one of fish collagen peptide and elastin peptide and sea buckthorn juice.
The peptide is a substance between amino acid and macromolecular protein, two or more amino acids are dehydrated and condensed to form a plurality of peptide bonds, so that a peptide is formed, the molecule of the peptide is only nano-sized, the peptide is easy to absorb by intestines, stomach, blood vessels, skin and the like, and the absorption rate of the peptide is far higher than that of the macromolecular protein. The fish collagen peptide is a high molecular functional protein, and can repair fractured and aged elastic fiber net and eliminate free radicals in vivo. In addition, the platelet can generate blood fiber to block wound, stimulate cell division and proliferation, differentiate and repair damaged cell, and heal wound.
Elastin peptide is the main component of elastic fiber, is insoluble in water, has elasticity capable of extending and contracting like rubber, has chain-locked and chain-locked amino acids, and can promote the formation of elastic fiber, maintain the structural integrity of elastic fiber, and provide intercellular adhesion and support.
Fructus Hippophae is a conventional medicinal material of Mongolian and Tibetan, and is dried mature fruit of Hippophae rhamnoides of Hippophae of Elaeagnaceae. According to records in Chinese pharmacopoeia, sea buckthorn has the effects of relieving cough and eliminating phlegm, promoting digestion and resolving stagnation, and activating blood and dissipating blood stasis, and can be used for treating cough with excessive phlegm, dyspepsia, abdominal pain due to dyspepsia, amenorrhea due to blood stasis, and traumatic injuries with swelling and blood stasis. The sea buckthorn fruit juice is rich in various amino acids required by human bodies, can promote the generation of collagen, also contains a large amount of vitamin E, vitamin A, flavone and the like, has special pharmacological properties of resisting fatigue, enhancing the activity of organisms, resisting cancer and the like, has the effects of reducing the cholesterol in blood plasma and reducing the content of the cholesterol in blood vessel walls, can prevent and treat hyperlipidemia and atherosclerosis, and has the effect of promoting wound healing.
Experiments show that the composition consisting of the fish collagen peptide and the sea buckthorn fruit juice and the composition consisting of the elastin peptide and the sea buckthorn fruit juice have excellent hematopoiesis promoting effect and vascular endothelial injury repairing effect. The fish collagen peptide and the sea buckthorn juice or the elastin peptide and the sea buckthorn juice can interact to improve the microcirculation of the organism.
The elastin peptide of the present invention is preferably bovine ligament elastin peptide.
The bovine ligament elastin peptide can improve vascular aging and protect cardiovascular health. Compared with other elastin peptides, the bovine ligament elastin peptide and the sea buckthorn juice have better promotion effect, and the effects of all components can be exerted to the maximum extent. If other elastin peptides are selected, the improvement effect is relatively poor.
Preferably, the composition comprises fish collagen peptide, bovine ligament elastin peptide and sea buckthorn juice.
Experiments prove that the composition consisting of the fish collagen peptide, the bovine ligament elastin peptide and the sea buckthorn fruit juice can greatly improve anemia symptoms caused by the ponatinib and has excellent repairing effect on vascular endothelial injury; compared with the composition only consisting of the fish collagen peptide and the sea buckthorn juice and the composition only consisting of the bovine ligament elastin peptide and the sea buckthorn juice, the composition can realize the dramatic improvement of the performance by only adding a small amount of the third component.
However, the present invention has found that by comparing the properties of the composition comprising fish collagen peptide, bonito elastin peptide and hippophae rhamnoides juice with those of the above-mentioned composition comprising two components, not any elastin peptide contributes to the improvement of the microcirculation improving function of the composition, and when elastin peptide is not bovine ligament elastin peptide, although it has the effect of improving blood vessel diameter, it has an adverse effect on the hematopoiesis promoting effect of the composition.
Preferably, in the composition, the mass ratio of the fish collagen peptide to the elastin peptide is (3-6): (0.075-0.2).
Experiments show that the ratio of the fish collagen peptide to the elastin peptide has very important influence on the performance of the composition, the fish collagen peptide and the elastin peptide can generate interaction, and when the ratio is different, the action results have great difference; too high or too low a proportion of fish collagen peptide results in a decrease in the promoting effect of both, and the improving effect on microcirculation is very limited. Experiments show that when the ratio of the fish collagen peptide to the elastin peptide meets the above limit, the hematopoiesis promoting effect can reach more than 38%, the blood vessel diameter improving effect can reach more than 28%, and the composition has excellent comprehensive performance.
Preferably, the fish collagen peptide comprises at least one of fish collagen peptide a, fish collagen peptide B, fish collagen peptide C;
the fish collagen peptide A contains more than or equal to 85 wt% of peptides with the molecular weight of less than or equal to 500 Da;
in the fish collagen peptide B, the content of peptides with the molecular weight of less than or equal to 1kDa is greater than or equal to 85 wt.%, and the content of peptides with the molecular weight of less than or equal to 500Da is less than or equal to 60 wt.%;
in the fish collagen peptide C, the content of peptides with the molecular weight of less than or equal to 3kDa is greater than or equal to 75 wt.%, the content of peptides with the molecular weight of less than or equal to 1kDa is less than or equal to 70 wt.%, and the content of peptides with the molecular weight of less than or equal to 500Da is less than or equal to 60 wt.%.
Further preferably, the fish collagen peptide is fish collagen peptide B; the bovine ligament elastin peptide has a molecular weight of less than or equal to 10kDa, wherein the content of peptides with molecular weights of less than or equal to 5kDa is greater than or equal to 80 wt.%.
Experiments show that the molecular weight of the fish collagen peptide and the bovine ligament elastin peptide has great influence on the efficacy, and the performance is adversely affected when the molecular weight is too low or too high, possibly because: the molecular weight is too small (the proportion of less than 500Da is too high), and the amino acid and the short peptide are easily decomposed in human body and are unstable; however, the molecular weight is too large (the ratio of less than 1kDa is too low), and the absorption of the peptide by the body is poor; in addition, there is a large difference in the efficacy profile of protein peptides of different molecular weights. The inventor finds that the composition prepared by selecting the fish collagen peptide B (the content of the peptide with the molecular weight of less than or equal to 1kDa is greater than or equal to 85 wt.%, and the content of the peptide with the molecular weight of less than or equal to 500Da is less than or equal to 60 wt.%) has the best effect on improving microcirculation.
Preferably, the total flavone content in the seabuckthorn fruit juice is more than 80mg/100g, and the total acid content is more than 3 wt.%. The flavonoids have antithrombotic and anti-platelet aggregation activities in vitro, and can improve blood rheological property; the acid in fructus Hippophae such as malic acid, succinic acid, citric acid, and ascorbic acid can act on human central nerve and enhance organism reaction capability. When the conditions are met, the composition prepared from the fish collagen peptide, the elastin peptide and the sea buckthorn juice has better hematopoiesis promoting effect and blood vessel diameter improving effect.
The invention also discloses a liquid preparation which comprises the composition for improving microcirculation.
The liquid preparation comprises the following components in percentage by mass: 3-6% of fish collagen peptide, 0.075-0.2% of elastin peptide, 60% of sea-buckthorn fruit juice and the balance of water.
In addition, the liquid preparation can also contain fruit and vegetable juice, a thickening agent and essence, and comprises the following components in percentage by mass: 3-6% of fish collagen peptide, 0.075-0.2% of elastin peptide, 60% of sea-buckthorn fruit juice, 0.01-2% of thickening agent, 0-2% of essence, 5-30% of fruit and vegetable juice and the balance of water.
The fruit and vegetable juice is at least one of concentrated jujube juice, concentrated apple juice, red grape raw juice, pomegranate raw juice, white grape concentrated juice, juicy peach concentrated juice, blueberry concentrated juice, concentrated medlar juice, concentrated roxburgh rose juice and concentrated mulberry juice; the thickener is at least one of gellan gum, pectin and konjac flour.
The invention also discloses a preparation method of the liquid preparation, which comprises the following steps:
(1) uniformly mixing the components according to the proportion to obtain a mixture;
(2) and homogenizing, degassing and sterilizing the mixture to obtain the liquid preparation.
In the step (2), the homogenizing pressure is 14-22 MPa, and the degassing vacuum degree is-0.05-0.06 MPa.
In the following examples, the experimental methods used were conventional unless otherwise specified, and the materials, reagents and the like used were commercially available unless otherwise specified.
The materials used in the examples and comparative examples are as follows:
fish collagen peptide a: peptide content of molecular weight of 500Da or less of 85 wt.% or more; the manufacturer is Guangdong Hua peptide Biotechnology Co., Ltd;
fish collagen peptide B: peptide content of molecular weight of less than or equal to 1kDa is greater than or equal to 85 wt.%, peptide content of molecular weight of less than or equal to 500Da is less than or equal to 60 wt.%; the manufacturer is Anhui Sheng Mei Nuo biotechnology limited;
fish collagen peptide C: peptide content of 3kDa or less is 75 wt.% or more, peptide content of 1kDa or less is 70 wt.% or less, and peptide content of 500Da or less is 60 wt.% or less; the manufacturer is Anhui Sheng Mei Nuo biotechnology limited;
bovine ligament elastin peptide: a peptide having a molecular weight of 10kDa or less, wherein the content of peptides having a molecular weight of 5kDa or less is 80 wt.%; the manufacturer is Guangdong China peptide biotechnology limited;
skipjack elastin peptide: a peptide having a molecular weight of 10kDa or less, wherein the content of peptides having a molecular weight of 5kDa or less is 80 wt.%; the manufacturer is Shanghai Chengcheng a health science and technology group company;
sea-buckthorn juice: the total flavone content is more than 80mg/100g, and the total acid content is more than 3 wt.%; the manufacturer is Baoderui (Hebei) health industry Co., Ltd;
thickening agent: the konjak flour is produced by Hubei consistent konjak Biotechnology GmbH;
essence: the food-grade essence meeting the national standard is prepared from Fengmei flavor (China) Co.Ltd;
fruit and vegetable juice: the blueberry concentrated juice is produced by Del run health food Co, Leling.
Example 1
In an embodiment of the composition for improving microcirculation, the composition of the present invention comprises fish collagen peptide B, bovine ligament elastin peptide and sea buckthorn fruit juice, wherein the mass ratio of fish collagen peptide B to bovine ligament elastin peptide is: bovine ligament elastin peptide: the seabuckthorn fruit juice is 6:0.2: 60.
Example 2
In an embodiment of the composition for improving microcirculation, the composition of the present invention comprises fish collagen peptide B, bovine ligament elastin peptide and sea buckthorn fruit juice, wherein the mass ratio of fish collagen peptide B to bovine ligament elastin peptide is: bovine ligament elastin peptide: the seabuckthorn fruit juice is 6:0.075: 60.
Example 3
In an embodiment of the composition for improving microcirculation, the composition of the present invention comprises fish collagen peptide B, bovine ligament elastin peptide and sea buckthorn fruit juice, and the mass ratio of fish collagen peptide B: bovine ligament elastin peptide: the seabuckthorn fruit juice is 3:0.2: 60.
Example 4
In an embodiment of the composition for improving microcirculation, the composition of the present invention comprises fish collagen peptide B, bovine ligament elastin peptide and sea buckthorn fruit juice, wherein the mass ratio of fish collagen peptide B to bovine ligament elastin peptide is: bovine ligament elastin peptide: the seabuckthorn fruit juice is 3:0.075: 60.
Example 5
In an embodiment of the composition for improving microcirculation, the composition of the present invention comprises fish collagen peptide B and sea buckthorn fruit juice, wherein the mass ratio of the fish collagen peptide B to the sea buckthorn fruit juice is: the seabuckthorn fruit juice is 3: 60.
Example 6
In an embodiment of the composition for improving microcirculation, the composition of the present invention is composed of bovine ligament elastin peptide and sea buckthorn fruit juice, and the mass ratio of the bovine ligament elastin peptide to the sea buckthorn fruit juice is: the seabuckthorn fruit juice is 0.075: 60.
Example 7
One embodiment of the composition for improving microcirculation according to the present invention is a composition comprising fish collagen peptide B and bovine ligament elastin peptide in a mass ratio of fish collagen peptide B: bovine ligament elastin peptide 3: 0.075.
Example 8
In an embodiment of the composition for improving microcirculation, the composition of the present invention comprises fish collagen peptide B, bonito elastin peptide and hippophae rhamnoides fruit juice, and the mass ratio of the fish collagen peptide B to the sea-buckthorn fruit juice is: skipjack elastin peptide: seabuckthorn fruit juice 3:0.075: 60.
Example 9
In an embodiment of the composition for improving microcirculation, the composition of the present invention comprises fish collagen peptide C, bovine ligament elastin peptide and sea buckthorn fruit juice, wherein the mass ratio of the fish collagen peptide C to the bovine ligament elastin peptide is: bovine ligament elastin peptide: the seabuckthorn fruit juice is 3:0.075: 60.
Example 10
In an embodiment of the composition for improving microcirculation, the composition of the present invention comprises fish collagen peptide a, bovine ligament elastin peptide and sea buckthorn fruit juice, wherein the mass ratio of fish collagen peptide a to bovine ligament elastin peptide is: bovine ligament elastin peptide: the seabuckthorn fruit juice is 3:0.075: 60.
Example 11
In an embodiment of the composition for improving microcirculation, the composition of the present invention comprises fish collagen peptide B and sea buckthorn fruit juice, wherein the mass ratio of the fish collagen peptide B to the sea buckthorn fruit juice is: the ratio of the seabuckthorn fruit juice is 3.2: 60.
Example 12
In an embodiment of the composition for improving microcirculation, the composition of the present invention is composed of bovine ligament elastin peptide and sea buckthorn fruit juice, and the mass ratio of the bovine ligament elastin peptide to the sea buckthorn fruit juice is: seabuckthorn fruit juice (3.075: 60).
Examples 13 to 24
Examples 13 to 24 are liquid preparations prepared from the compositions of examples 1 to 12, respectively, wherein the liquid preparations contain water as a component other than the composition; the mass percentage of the composition in the liquid preparation described in example 13 is 66.2%, the mass percentage of the composition in the liquid preparation described in example 14 is 66.075%, the mass percentage of the composition in the liquid preparation described in example 15 is 63.2%, the mass percentage of the composition in the liquid preparation described in example 16 is 63.075%, the mass percentage of the composition in the liquid preparation described in example 17 is 63%, the mass percentage of the composition in the liquid preparation described in example 18 is 60.075%, the mass percentage of the composition in the liquid preparation described in example 19 is 3.075%, the mass percentage of the composition in the liquid preparation described in example 20 is 63.075%, the mass percentage of the composition in the liquid preparation described in example 21 is 63.075%, the mass percentage of the composition in the liquid preparation described in example 22 is 63.075%, and the mass percentage of the composition in the liquid preparation described in example 23 is 63.2%, the composition contained in the liquid preparation described in example 24 was 63.075% by mass.
The preparation method of the liquid preparation described in embodiments 13 to 24 includes: dispersing the composition in water, homogenizing under 20MPa for 3min, degassing to maintain vacuum degree of-0.05 MPa, and sterilizing at 120 deg.C for 30s to obtain the liquid preparation.
Example 25
In an embodiment of the liquid formulation according to the present invention, the liquid formulation of this embodiment includes the composition for improving microcirculation as described in example 1, and the liquid formulation of this embodiment includes the following components by mass percent: 66.2 percent of the composition, 0.5 percent of thickening agent, 1 percent of essence, 10 percent of fruit and vegetable juice and the balance of water.
The preparation method of the liquid preparation described in this example is as follows:
(1) dissolving a thickening agent in water, and stirring for 10min to obtain a solution A;
(2) adding fructus Hippophae juice and fruit and vegetable juice into solution A, stirring for 10min, adding fish collagen peptide B, cattle ligament elastin peptide and essence, stirring to dissolve uniformly to obtain mixture;
(3) and (3) homogenizing and degassing the mixture obtained in the step (2) for 3min under 20MPa, degassing to keep the vacuum degree at-0.05 MPa, and sterilizing at 120 ℃ for 30s to obtain the liquid preparation.
Microcirculation improvement efficacy experiment
And (3) detecting heart staining intensity indexes by randomly selecting AB-line wild zebra fish embryos of 5 days (5dpf) after fertilization, and detecting the diameter change of blood vessels by selecting 5dpf transgenic blood vessel green fluorescent Fli-1 strain zebra fish. The method is carried out in a natural pairing propagation mode, 15 groups are randomly divided, 15 tails of each group are provided with a positive control group, a normal control group, a model control group and experimental groups 1-12. And (3) adding ponatinib aqueous solution with the ponatinib concentration of 4.00 mu g/mL into other experimental groups except the normal control group to establish a zebra fish anemia model. The positive control group was administered with an aspirin aqueous solution having an aspirin concentration of 45.0 μ g/mL, the experimental groups 1 to 12 were administered with an aspirin aqueous solution having a concentration of 1.25 μ L/mL, respectively, with the samples of examples 13 to 24, but the model control group was not administered, and the samples were treated at 28 ℃ for 18 hours, followed by staining with an o-dianisidine staining solution for 5 minutes (preparation of o-dianisidine staining solution: 30mg of o-dianisidine, 41mg of sodium acetate, and 1mL of 30 wt.% hydrogen peroxide were weighed, and the volume was determined with a 50mL volumetric flask with 40 wt.% absolute ethanol).
(1) Effect on anemia-ameliorating Effect
5 zebra fish were randomly selected for each experimental group, photographed under a microscope and data collected, and the hematopoiesis promoting effect was analyzed by cardiac erythrocyte staining intensity S, the test result of which is shown in fig. 1. The hematopoiesis promoting efficacy is calculated as follows, and table 1 and fig. 2 are the results of hematopoiesis promoting efficacy evaluation:
the significant difference compared with the model control group is significant.
TABLE 1 evaluation results of hematopoietic promoting efficacy
As can be seen from Table 1, when the P value of the normal control group is less than 0.001, the model is successfully established. Compared with the model control group, the positive control group has the P less than 0.001, and the hematopoiesis promoting effect of 67.21%, and the result shows that the aspirin has the obvious hematopoiesis promoting effect.
Compared with the model control group, P of the experimental groups 1-7 and the experimental groups 10-12 is less than 0.05, and the results show that the composition consisting of the fish collagen peptide and the sea buckthorn juice, the composition consisting of the bovine ligament elastin peptide and the sea buckthorn juice and the composition consisting of the fish collagen peptide, the bovine ligament elastin peptide and the sea buckthorn juice have good hematopoiesis promoting effects.
The experimental groups 1-4 are compared with a model control group, P is less than 0.001, compared with a positive control group, P is less than 0.05, the hematopoietic promotion effects of the experimental groups 1-4 are respectively 133.49%, 130.54%, 122.55% and 118.35%, the hematopoietic promotion effects are obviously superior to those of other experimental groups, and the results show that the fish collagen peptide, the bovine ligament elastin peptide and the sea buckthorn fruit juice have a synergistic effect, so that the hematopoietic promotion performance of the composition can be obviously improved.
The test results of the comparison of the experimental group 8 and the experimental group 4 show that not all elastin peptides can cooperate with fish collagen peptide and sea buckthorn juice to improve hematopoiesis promotion effect, and only when the elastin peptides are bovine ligament elastin peptides, the corresponding effect can be achieved.
The test results of the experiment group 4 and the experiment groups 9 and 10 are compared to find that the molecular weight of the fish collagen peptide also has great influence on the hematopoiesis promotion effect, the fish collagen peptide with the peptide content of less than or equal to 1kDa and less than or equal to 85 wt.% and the peptide content of less than or equal to 500Da is selected, the hematopoiesis promotion effect is 2-3 times that of other fish collagen peptides, 118% can be achieved, and the fish collagen peptide has extremely excellent performance. When the content of peptides below 500Da in fish collagen peptide is too high (as in experimental group 10), the hematopoiesis promoting effect is only 53.45%, and when the content of peptides with high molecular weight in fish collagen peptide is too high (as in experimental group 9), the hematopoiesis promoting effect is further reduced to 38.82%.
(2) Effect on the protective action of the vascular endothelium
5 zebra fish were randomly selected for each experimental group and photographed under a microscope and data were collected, and the protective effect of the samples on the vascular endothelial injury of zebra fish induced by ponatinib was evaluated in the statistical sense of the internode vascular diameter (D), and fig. 3 is a test chart of the internode vascular diameter. The blood vessel diameter improvement efficacy calculation formula is as follows, and the test results are shown in table 2 and fig. 4:
the significant difference from the model control group is significant.
TABLE 2
As shown in Table 2, P was < 0.001 in the normal control group compared with the model control group, and the results indicated that the model was successfully constructed. Compared with the model control group, the positive control group has the P less than 0.001, and the result shows that the aspirin has the functions of improving the diameter of the blood vessel and protecting the endothelium of the blood vessel. In addition, compared with the model control group, the P of the experimental group 1-12 is less than 0.05, and the effect of improving the blood vessel diameter can reach more than 16%, and the results show that the composition consisting of the fish collagen peptide and the sea buckthorn fruit juice, the composition consisting of the bovine ligament elastin peptide and the sea buckthorn fruit juice and the composition consisting of the fish collagen peptide, the bovine ligament elastin peptide and the sea buckthorn fruit juice have excellent effect of improving the blood vessel diameter. For vascular endothelial injury induced by ponatinib, both skipjack elastin peptide and bovine ligament elastin peptide can act with fish collagen peptide and sea buckthorn juice, and have good effects of improving blood vessel diameter and repairing vascular endothelial injury.
Compared with a positive control group, P of the experimental groups 1-4 is less than 0.05, the experimental groups 5-7 and the experimental groups 11-12 have no significant difference compared with the positive control group, and the results show that under the condition that the elastin peptide is bovine ligament elastin peptide, the three combinations of the composition have better effects than two combinations, and are superior to the normal control group, the results show that the three have a synergistic effect, the effect of improving the diameter of the blood vessel of the experimental group 3 is about 1.7 times that of the experimental group 11, and the effect of improving the diameter of the blood vessel of the experimental group 4 is about 1.6 times that of the experimental group 12.
Compared with the model control group, the P of the experimental group 8 is less than 0.05, and the effect of improving the blood vessel diameter is 16.26%, which indicates that the elastin peptide derived from bonito has the effect of improving the blood vessel diameter, but compared with the experimental group 4, the effect of improving the blood vessel diameter of the experimental group 4 is 58.63%, which is better, and indicates that the elastin peptide derived from bovine ligament can improve the blood vessel diameter by cooperating with the fish collagen peptide and the sea buckthorn juice.
Compared with a model control group, the experimental group 9 has the P less than 0.05 and the blood vessel diameter improving effect of 28.53 percent, and the experimental group 10 has the P less than 0.001 and the blood vessel diameter improving effect of 38.90 percent, which shows that the compounding of the three fish collagen peptides, the bovine ligament elastin peptide and the sea buckthorn fruit juice can repair the blood vessel endothelium injury; however, compared with the experimental group 6 (the effect of improving the blood vessel diameter is 38.88%), after the fish collagen peptide a or the fish collagen peptide C is added, the performance of the composition is not obviously changed and is even slightly reduced, the result shows that the effect results of the fish collagen peptides with different molecular weights, the elastin peptides and the sea buckthorn fruit juice are different, and only when the fish collagen peptide is the fish collagen peptide B, the fish collagen peptides, the bovine ligament elastin peptides and the sea buckthorn fruit juice can be ensured to synergistically improve the blood vessel diameter and repair the vascular endothelial injury caused by ponatinib.
The test results in tables 1-2 show that the composition prepared from bovine ligament elastin peptide and sea buckthorn fruit juice, the composition prepared from fish collagen peptide and sea buckthorn fruit juice, and the composition prepared from bovine ligament elastin peptide, fish collagen peptide and sea buckthorn fruit juice can all play a role in improving and repairing anemia and vascular endothelial injury caused by ponatinib, and the bovine ligament elastin peptide, fish collagen peptide B (the peptide content with the molecular weight of less than or equal to 1kDa is greater than or equal to 85 wt.%, and the peptide content with the molecular weight of less than or equal to 500Da is less than or equal to 60 wt.%) and sea buckthorn fruit juice have synergistic effects, so that the hematopoiesis promotion effect can be remarkably improved, and the blood vessel diameter can be improved.
When skipjack elastin peptide, fish collagen peptide B and sea buckthorn fruit juice are selected for compounding, adverse effect is generated on the hematopoietic promotion effect of the composition; when the fish collagen peptide A or the fish collagen peptide C is compounded with bovine ligament elastin peptide and sea buckthorn fruit juice, the effect of improving the blood vessel diameter of the composition is adversely affected. The kinds of fish collagen peptide and elastin peptide have great influence on hematopoiesis promoting effect and blood vessel diameter improving effect.
Finally, it should be noted that the above embodiments are only used for illustrating the technical solutions of the present invention and not for limiting the protection scope of the present invention, and although the present invention has been described in detail with reference to the preferred embodiments, it should be understood by those skilled in the art that modifications or equivalent substitutions can be made on the technical solutions of the present invention without departing from the spirit and scope of the technical solutions of the present invention.
Claims (15)
1. A composition for improving microcirculation, comprising at least one of fish collagen peptide, elastin peptide and sea buckthorn juice.
2. The composition of claim 1, wherein the elastin peptide is a bovine ligament elastin peptide.
3. The composition of claim 2, wherein the composition comprises fish collagen peptide, elastin peptide, and sea buckthorn juice.
4. The composition according to claim 3, wherein the mass ratio of the fish collagen peptide to the elastin peptide in the composition is (3-6): (0.075-0.2).
5. The composition of claim 3, wherein the fish collagen peptide comprises at least one of fish collagen peptide A, fish collagen peptide B, and fish collagen peptide C;
the fish collagen peptide A contains more than or equal to 85 wt% of peptides with the molecular weight of less than or equal to 500 Da;
in the fish collagen peptide B, the content of peptides with the molecular weight of less than or equal to 1kDa is greater than or equal to 85 wt.%, and the content of peptides with the molecular weight of less than or equal to 500Da is less than or equal to 60 wt.%;
in the fish collagen peptide C, the content of peptides with the molecular weight of less than or equal to 3kDa is greater than or equal to 75 wt.%, the content of peptides with the molecular weight of less than or equal to 1kDa is less than or equal to 70 wt.%, and the content of peptides with the molecular weight of less than or equal to 500Da is less than or equal to 60 wt.%.
6. The composition of claim 5, wherein the fish collagen peptide is fish collagen peptide B; the molecular weight of the elastin peptide is less than or equal to 10kDa, wherein the content of peptides with the molecular weight of less than or equal to 5kDa is more than or equal to 80 wt.%.
7. The composition of claim 1, wherein the hippophae rhamnoides juice has a total flavone content of greater than 80mg/100g and a total acid content of greater than 3 wt.%.
8. A liquid formulation comprising the composition of any one of claims 1 to 7.
9. The liquid preparation according to claim 8, comprising the following components in percentage by mass: 3-6% of fish collagen peptide, 0.075-0.2% of elastin peptide, 60% of sea-buckthorn fruit juice and the balance of water.
10. The liquid formulation of claim 8, further comprising at least one of a thickener, a juice, and a flavor.
11. The liquid preparation according to claim 10, comprising the following components in percentage by mass: 3-6% of fish collagen peptide, 0.075-0.2% of elastin peptide, 60% of sea buckthorn fruit juice, 0.01-2% of thickening agent, 0-2% of essence, 5-30% of fruit and vegetable juice and the balance of water.
12. A method for preparing a liquid formulation according to any one of claims 9 to 11, comprising the steps of:
(1) uniformly mixing the components according to the proportion to obtain a mixture;
(2) and homogenizing, degassing and sterilizing the mixture to obtain the liquid preparation.
13. The method according to claim 12, wherein in the step (2), the homogenization condition is 14 to 22MPa, and the deaeration condition is-0.05 to-0.06 MPa.
14. Use of a liquid formulation according to any one of claims 8 to 11 in the preparation of a product for promoting hematopoiesis.
15. Use of a liquid formulation according to any one of claims 9 to 11 in the preparation of an article of manufacture for improving the diameter of a blood vessel.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210851308.1A CN115005434B (en) | 2022-07-20 | 2022-07-20 | Composition and liquid preparation for improving microcirculation and preparation method and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210851308.1A CN115005434B (en) | 2022-07-20 | 2022-07-20 | Composition and liquid preparation for improving microcirculation and preparation method and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN115005434A true CN115005434A (en) | 2022-09-06 |
| CN115005434B CN115005434B (en) | 2023-04-11 |
Family
ID=83080254
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202210851308.1A Active CN115005434B (en) | 2022-07-20 | 2022-07-20 | Composition and liquid preparation for improving microcirculation and preparation method and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN115005434B (en) |
Citations (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102266313A (en) * | 2011-05-17 | 2011-12-07 | 杭州环特生物科技有限公司 | Method for establishing zebra fish thrombosis model and method for screening antithrombotic drug and thrombosis producing drug |
| CN106667982A (en) * | 2017-02-24 | 2017-05-17 | 北京中医药大学 | Method for preparing zebrafish thrombus model |
| CN107836607A (en) * | 2017-11-28 | 2018-03-27 | 广州颜如玉医药科技有限公司 | A kind of fish skin collagen oligopeptide blueberries drink and preparation method thereof |
| CN108261539A (en) * | 2018-02-27 | 2018-07-10 | 南京圣诺生物科技实业有限公司 | A kind of composition, preparation method and the usage for antithrombotic |
| CN109363164A (en) * | 2018-11-22 | 2019-02-22 | 赛杜恳医药生物科技（上海）有限公司 | A kind of oral solution and preparation method thereof containing small-molecular peptides that can improve microcirculation |
| CN109820123A (en) * | 2018-11-22 | 2019-05-31 | 赛杜恳医药生物科技（上海）有限公司 | A kind of plant beverage and preparation method thereof improving microcirculation |
| CN111903889A (en) * | 2020-08-12 | 2020-11-10 | 安徽盛美诺生物技术有限公司 | Formula of double-peptide combined skin-beautifying solid beverage |
| CN112425785A (en) * | 2020-11-25 | 2021-03-02 | 湖南宜贝生物科技有限公司 | Composition with effects of maintaining beauty and keeping young and preparation method and application thereof |
| CN112956703A (en) * | 2021-04-09 | 2021-06-15 | 果畅(苏州)健康科技有限公司 | Collagen peptide health food and production method thereof |
| CN113512108A (en) * | 2021-03-23 | 2021-10-19 | 广州天启生物科技有限公司 | Marine fish skin collagen oligopeptide and preparation method and application thereof |
| CN113663051A (en) * | 2020-04-30 | 2021-11-19 | 广西嘉盈生物科技有限公司 | Composition of skipjack elastin peptide and collagen oligopeptide and preparation method thereof |
-
2022
- 2022-07-20 CN CN202210851308.1A patent/CN115005434B/en active Active
Patent Citations (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102266313A (en) * | 2011-05-17 | 2011-12-07 | 杭州环特生物科技有限公司 | Method for establishing zebra fish thrombosis model and method for screening antithrombotic drug and thrombosis producing drug |
| CN106667982A (en) * | 2017-02-24 | 2017-05-17 | 北京中医药大学 | Method for preparing zebrafish thrombus model |
| CN107836607A (en) * | 2017-11-28 | 2018-03-27 | 广州颜如玉医药科技有限公司 | A kind of fish skin collagen oligopeptide blueberries drink and preparation method thereof |
| CN108261539A (en) * | 2018-02-27 | 2018-07-10 | 南京圣诺生物科技实业有限公司 | A kind of composition, preparation method and the usage for antithrombotic |
| CN109363164A (en) * | 2018-11-22 | 2019-02-22 | 赛杜恳医药生物科技（上海）有限公司 | A kind of oral solution and preparation method thereof containing small-molecular peptides that can improve microcirculation |
| CN109820123A (en) * | 2018-11-22 | 2019-05-31 | 赛杜恳医药生物科技（上海）有限公司 | A kind of plant beverage and preparation method thereof improving microcirculation |
| CN113663051A (en) * | 2020-04-30 | 2021-11-19 | 广西嘉盈生物科技有限公司 | Composition of skipjack elastin peptide and collagen oligopeptide and preparation method thereof |
| CN111903889A (en) * | 2020-08-12 | 2020-11-10 | 安徽盛美诺生物技术有限公司 | Formula of double-peptide combined skin-beautifying solid beverage |
| CN112425785A (en) * | 2020-11-25 | 2021-03-02 | 湖南宜贝生物科技有限公司 | Composition with effects of maintaining beauty and keeping young and preparation method and application thereof |
| CN113512108A (en) * | 2021-03-23 | 2021-10-19 | 广州天启生物科技有限公司 | Marine fish skin collagen oligopeptide and preparation method and application thereof |
| CN112956703A (en) * | 2021-04-09 | 2021-06-15 | 果畅(苏州)健康科技有限公司 | Collagen peptide health food and production method thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN115005434B (en) | 2023-04-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US10117910B2 (en) | Composition of natural vitamin C and fish scale collagen peptide and preparation method thereof | |
| CN110522038A (en) | The healthy food of composite blueberry, Black Box Tracing and Isin glue collagen peptide | |
| WO2016015391A1 (en) | Pharmaceutical composition for treating cardiovascular or cerebrovascular diseases and preparation method therefor | |
| CN105662942A (en) | Composition for keeping skin's moisture and resisting oxidation as well as preparation method thereof | |
| CN113080459A (en) | Preparation method of hyaluronic acid oral liquid | |
| CN1810137A (en) | Health tea | |
| CN103005255A (en) | Chitosan oligosaccharide-collagen peptide compound health food and preparation method thereof | |
| CN111514161B (en) | Anti-oral ulcer preparation and application thereof | |
| CN115005434B (en) | Composition and liquid preparation for improving microcirculation and preparation method and application thereof | |
| KR102485612B1 (en) | Composition for promoting absorption of collagen and synthesis of collagen | |
| LU500771B1 (en) | Composition for preventing and treating alcoholic liver injury and preparation method and application thereof | |
| RU2492867C1 (en) | Biologically active additive | |
| US4824673A (en) | New drugs based on extracts of algae, and corresponding formulations | |
| CN112245387B (en) | Composition and preparation method of m-hydroxylamine bitartrate injection | |
| KR20050101143A (en) | Methods and composition for the prevention and improvement of degenerative arthritis including glucosamin | |
| CN114158738A (en) | Antioxidant beautifying cubilose collagen peptide composition and preparation method thereof | |
| CN102058617B (en) | Sodium heparin vitamin E gel and preparation method thereof | |
| EP3756477A1 (en) | Nano collagen peptide chelate mineral and method for preparing the same | |
| CN110755623A (en) | Western medicine external ointment and preparation method thereof | |
| CN105288715A (en) | Operation suture with function of antibiosis and preparation technology thereof | |
| CN104666321A (en) | Film for treating dental ulcer and preparation method of film | |
| CN114468288A (en) | Hyaluronic acid oral liquid easy to absorb and application | |
| Liu | 7 Surprising Benefits of the AMAZING Aloe Vera Plant! | |
| CN116711860A (en) | Oral liquid containing small molecule peptide capable of improving microcirculation and preparation method thereof | |
| CN118236339A (en) | Vitamin C and dihydroquercetin compound effervescent tablet and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |